Regional variation in the incidence rate and sex ratio of multiple sclerosis in Scotland 2010-2017: findings from the Scottish Multiple Sclerosis Register by Kearns, Patrick et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regional variation in the incidence rate and sex ratio of multiple
sclerosis in Scotland 2010-2017: findings from the Scottish
Multiple Sclerosis Register
Citation for published version:
Kearns, P, Paton, M, O’Neill, M, Waters, C, Colville, S, McDonald, J, Young, IJB, Pugh, D, O’Riordan, J,
Weller, B, MacDougall, N, Clemens, T, Dibben, C, Wilson, J, Castro, MC, Ascherio, A, Chandran, S &
Connick, P 2019, 'Regional variation in the incidence rate and sex ratio of multiple sclerosis in Scotland
2010-2017: findings from the Scottish Multiple Sclerosis Register', Journal of Neurology.
https://doi.org/10.1007/s00415-019-09413-x
Digital Object Identifier (DOI):
10.1007/s00415-019-09413-x
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of Neurology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
Vol.:(0123456789) 
Journal of Neurology 
https://doi.org/10.1007/s00415-019-09413-x
ORIGINAL COMMUNICATION
Regional variation in the incidence rate and sex ratio of multiple 
sclerosis in Scotland 2010–2017: findings from the Scottish Multiple 
Sclerosis Register
Patrick K. A. Kearns1,2,3  · Martin Paton3 · Martin O’Neill3 · Chrissie Waters3 · Shuna Colville1 · James McDonald4 · 
Ian J. B. Young5 · Dan Pugh5 · Jonathon O’Riordan6 · Belinda Weller1 · Niall MacDougall7 · Tom Clemens8 · 
Chris Dibben8 · James F. Wilson9,10 · Marcia C. Castro11 · Alberto Ascherio12 · Siddharthan Chandran1,2 · 
Peter Connick1,2
Received: 12 May 2019 / Revised: 29 May 2019 / Accepted: 30 May 2019 
© The Author(s) 2019
Abstract
Background Fifteen regional studies published over the last six decades surveying prevalence, mortality and hospital admis-
sions have suggested that Scotland is amongst the highest risk nations for multiple sclerosis (MS) in the world. However, 
substantial intranational variation in rates (between regions) has been described in numerous countries, including in the 
only previous Scottish national survey, which used hospital admission data, to address this issue. Against this backdrop, 
the Scottish Multiple Sclerosis Register (SMSR) was established in 2010 to prospectively collect nationally comprehensive 
incidence data and to allow for regional comparisons.
Methods Here, we present the SMSR and analyse the variation in crude and age–sex standardized incidence rates, lifetime 
risk (cumulative incidence), and the sex distribution of cases and rates, between the 14 administrative Health Boards or 
regions of Scotland: 01 January 2010 to 31 December 2017.
Results The overall incidence rate for Scotland was 8.76/100,000 person-years (standardized: 8.54). Regional incidence rates 
varied significantly—up to threefold—between Health Boards (p < 1 × 10–13). The national female-to-male sex ratio was 2.3:1, 
but this too varied regionally (outlier regions result in a range from 1.0 to 4.2:1). Lifetime risk ranged from 19.9/1000 for 
females in Orkney (58.98°N) to 1.6/1000 for males in the Borders (55.60°N). Comparison with a previous national survey 
suggests that these differences are longstanding. In 6 of 14 regions the lifetime risk for women exceeds 1%.
Conclusions This study introduces a national incidence register: a valuable research tool and the result of substantial public 
investment. The wide variation in incidence rates and sex ratios between regions, in a relatively homogenous population, 
raises questions for future study.
Keywords Epidemiologic methods · Central nervous system diseases · Registry · Autoimmune diseases · Epidemiology
Introduction
Broad consensus exists for genetic susceptibility interacting 
with potent environmental risk factors in the pathogenesis 
of multiple sclerosis (MS) [1–3]. Nevertheless, a detailed 
account of the causal chain remains elusive. One aspect 
of MS epidemiology that remains unexplained is the well 
recognized within-country regional variation in MS rates 
[4–7]. In many countries, differences in regional rates have 
been wide (up to tenfold) and persistent in the same regions 
across period cohorts, i.e. relative differences in regional 
rates persist despite different generations of patients being 
diagnosed by different generations of neurologists [5]. 
There may be an opportunity to identify novel contributors 
to aetiology by studying these variations, because the list of 
possible causes (genetic or environmental) is more limited 
between relatively similar sub-national regional populations 
than between disparate international ones. Addressing this, 
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however, will require high quality and geographically pre-
cise epidemiological datasets that can guide targeted genetic, 
seroepidemiological, and biome research.
Scotland represents a powerful environment to study MS 
due its very high incidence of the disease. This is reflected 
in a strong history of Scottish MS epidemiological study 
over several decades. Fifteen surveys have been published 
since the first by Sutherland in 1956 [8], which have con-
sistently shown a pattern of increasing prevalence and high 
rates by international standards [9, 10]. In addition, there 
are technical advantages particularly for making between-
region comparisons in Scotland. These include a stable 
and homogeneous population of 5.3M, a unitary and free 
health-care provider system (NHS) and e-health infrastruc-
tural strengths such as a nationwide patient identifier (CHI) 
assigned at birth. The CHI enables lifelong tracking for all 
contact with public services including vaccinations, hospital 
admissions, prescriptions, etc., and consequently the crea-
tion and alignment of detailed datasets of social and health 
care interactions. However, only one study has attempted to 
document within-Scotland variation in rates using a national 
sample covering a single period [11].
In 2010, recognizing MS as an important public health 
problem, the Scottish Government established the Scottish 
MS Register (SMSR), a prospective incidence register, man-
dating the recording of all newly diagnosed cases of MS. 
The primary purpose was to ensure that all persons diag-
nosed with MS were offered contact with an MS specialist 
nurse within ten working days of diagnosis and, secondarily, 
to routinely and systematically collect comprehensive data 
for epidemiological research [12]. Our aims in this paper are 
twofold: first to present the SMSR to highlight its potential 
as a research tool, and second to analyse the first 8 years of 
incidence data captured therein to study the regional vari-
ability in MS rates between the 14 “Health Board” regions 
of Scotland.
Methods
Data
The SMSR aims for comprehensive ascertainment by cou-
pling routine data collection with a continuous audit of ser-
vice quality. The ten working day requirement is an “essen-
tial criteria” of a national standard [Standard 15.2 of the 
Clinical Standards for Neurology Services (2009)] which 
requires Health Boards to meet this target [13]. MS special-
ist nurses are obliged to report data on this outcome accu-
rately and promptly after diagnosis which is then confirmed 
by the treating neurologist. Completeness and accuracy are 
continuously monitored by Information Services Division 
(ISD) of National Health Service (NHS) National Services 
Scotland (NSS).
Individual level SMSR data, including age, date and 
address at the time of diagnosis, were extracted in an 
anonymized form. Census data, publically available for 
Health Board populations, were used for the denominators 
for all calculations based on the Scottish national census 
2011 (https ://www.scotl andsc ensus .gov.uk/) [14].
Inclusion and exclusion criteria
Adults (legally persons ≥ 16 years old), newly diagnosed 
with MS in Scotland after 01/01/2010, as defined by the 
Revised McDonald Criteria 2005 [15], are routinely 
recorded on the SMSR. We included all those persons with 
MS (pwMS) on the register diagnosed up to 31 December 
2017. Persons with possible MS or clinically isolated syn-
drome are excluded (https ://www.msr.scot.nhs.uk/).
Health Board geography
Scotland has a universal health care system, publically 
owned and operated, free at the point of use (NHS). The 
great majority of health care in Scotland is delivered by the 
NHS. Private neurologists typically also work in the NHS 
(and refer to MS services via specialist nurses) and probably 
all pwMS in Scotland, who have been diagnosed, use some 
NHS services. NHS Scotland is separated into 14 territorial 
Health Boards which were the aggregate unit of geography 
used in this study. Health Board latitude was defined as the 
latitude of the administrative centre.
Ethics
Formal research ethics approval was not required as audit 
data were de-identified, but peer-review by the SMSR steer-
ing committee and independent internal (ISD) review by 
an NHS employed consultant of public health ensured the 
project was in line with the aims and objectives of the SMSR 
and consistent with usual public health practice for the use 
of routinely collected data obtained without explicit consent.
Statistical analyses
To allow for external comparisons unconfounded by popula-
tion age–sex structure, direct-standardization of incidence 
rates was performed to the 2013 European Standard Popula-
tion (ESP) (https ://www.ons.gov.uk). Indirect standardiza-
tion of regional rates was conducted using national rates as 
the referent for between-health-board comparisons. Maps 
were created using QGIS v2.18.23 using publicly available 
shapefiles (data.gov.uk). The cartogram was created using 
GeoDa v1.12.
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Lifetime (risk) cumulative incidence rates (CIR) were 
calculated for each region as:
where i = age stratum, ID = incidence density for the 
ith age stratum, and wi = the width in years of the ith age 
stratum. This measure has the advantage of incorporating 
(in ID strata) the population size of the strata and so is 
comparable across populations of different age-structures. 
CIRs are the proportion of population affected over a given 
period, here calculated to reflect lifetime risk and are pre-
sented per 1000 persons.
Statistical significance was defined using an α of 0.05 
throughout. Omnibus test of statistical significance of 
variation in rates by region was tested using a 14-sample 
Chi-squared test. Associations were inspected visually 
and where appropriate linear relationships were analysed 
using ordinary and weighted least squares regression mod-
els. Pearson’s correlation coefficients were generated for 
bivariate analyses. Simulated rates under a null hypothesis 
of complete spatial randomness were calculated by ran-
domly allocating each of n = 3680 cases to Health Boards 
proportional to population size 100,000 times in order to 
create empirical distributions under the null. p values for 
observed rates occurring under the null were calculated by 
comparing observed rates to the empirically derived null 
distributions and correcting for m = 14 independent tests 
using the Bonferroni method (α/m). Statistical analyses, 
simulations and tests were conducted using R and R Studio 
(v. 3.5.1).
The dataset used here is available subject to approval of 
the SMSR steering committee and NHS NSS ISD.
Results
The Scottish MS Register
3680/3716 (99.0%) cases were included in the regional 
analyses with 36 persons excluded due to incomplete 
address data (Fig. 1).
The resident populations within Health Boards are pre-
sented in Table 1, showing regional variation in population 
number and density. The majority of Scotland’s population 
lives in the “central belt” which includes the two larg-
est cities of Glasgow and Edinburgh. 98% of the Scottish 
population lives on the mainland and there are some 790 
islands, 94 permanently inhabited which are broadly sepa-
rated into four main island groups: The Outer Hebrides 
CIR = 1 − exp
[
−
n∑
i=1
(IDi)wi
]
,
(which make up the Western Isles Health Board), The 
Inner Hebrides (which are grouped in the Highland Health 
Board), Orkney and Shetland.
Regional incidence 2010–2017
The incidence we refer to throughout this study is the inci-
dence of diagnosis rather than the incidence of disease onset. 
The crude MS incidence rate for the Scottish population as 
a whole was 8.76/105 person-years (pys) (directly standard-
ized to ESP, 8.54/105pys). The national crude incidence rate 
for females was 11.70/105 pys and for males 5.48/105 pys. 
The ratio of female case count to male was 2.27 (2.14 for 
adjusted rate ratio). The age range of subjects at the time of 
diagnosis was 65.8 years with mean age of 41.34 (SD 12.03) 
years and median of 40 years. Age-specific incidence rates 
(Fig. 2) were used to calculate indirectly age-standardized 
incidence rates (supplementary Table 1).
Crude and indirectly age-standardized rates by Health 
Board, over the study period, are presented in Table 1 and 
Fig. 3, demonstrating significant variation in the incidence 
rate by region ( X2
13
= 94.7 , two-sided p < 1 × 10–13). Orkney 
was the highest incidence region in Scotland and there was 
good agreement between crude and standardized rates indi-
cating that differences in population age-structure were not 
large contributors to apparent differences in rates. Lanark-
shire (6.34), the Borders (6.66), Lothian (6.85) and Greater 
Glasgow and Clyde (7.21) formed a contiguous band of the 
lowest incidence regions, with adjusted rates approximately 
one-third that of Orkney (18.35) and one-half that of Shet-
land (11.01), Highland (12.07) and Tayside (12.81), the lat-
ter being the highest incidence region on the mainland.
Our finding of differences in incidence rates by region 
agree with those previously estimated by Handel et al. [11] 
using a different method for case ascertainment [hospital 
admissions—Scottish Morbidity Records 01 (SMR01)]. 
We replicate the threefold between-health-board variation 
described in that study (r = 0.85, p < 0.001), finding the 
same regions to be high and low incidence, despite the dif-
ferent patient cohort: 1997–2009 in Handel et al. [11] and 
2010–2017 in our study.
We considered whether ascertainment discrepancies, aris-
ing from systematic differences in time from first symptoms 
to diagnosis, might have contributed to these results and we 
hypothesized that, if so, this might be reflected in differences 
in distribution of age at diagnosis (Fig. 4). Whilst visual 
inspection did not suggest obvious systematic differences 
between groups, omnibus testing of the age distribution by 
region using Kruskal–Wallis test demonstrated a signifi-
cant difference ( X2
14
 = 33.6, p = 0.002). However, this was 
not unexpected given the large number of cases and power 
to detect small deviations from uniformity, and in post hoc 
(Dunn’s) analyses only two (of 91) pairwise comparisons 
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yielded a significant difference after correcting for multiple 
testing using the false discovery method: the median diag-
nosis in Glasgow occurred significantly earlier than in Forth 
Valley (+ 3.3 years, p = 0.02) and in Grampian (+ 3.7 years, 
p = 0.01) Health Boards.
In addition to variation in incidence rates, we found varia-
tion in the sex ratio of cases between regions (Table 2) albeit 
this was chiefly driven by two outlier regions in the Borders 
and Shetland: there was no significant difference across all 
regions (X2
13
= 16.6, p = 0.22) . The (F:M) sex ratio was most 
equitable in Shetland 1.0 (n = 10:10, lat = 60.39°N) and most 
inequitable in the borders 4.18 (n = 46:11, lat = 55.58°N). 
Adjusting for differences in regional population age–sex 
structure accounted for little of this difference. A signifi-
cant negative linear relationship of sex ratio on latitude was 
detected by ordinary least squares regression (β = − 1.30, 
p = 0.03)—i.e. relatively more females were affected at lower 
latitudes and the sex ratio was more equitable at higher lati-
tudes. However, again the outliers drive this effect. No sig-
nificant linear trend with latitude exists amongst the other 
Health Boards after excluding Shetland and the Borders 
(β = − 0.94, p = 0.56) and both areas have low numbers of 
cases. The effect is similarly not significant when accounting 
for population in weighted analyses (β = − 0.88, p = 0.09).
We found that the lifetime risk of MS in Scotland is 
6.55 per 1000 persons for the country as a whole and, 
Fig. 1  Flow diagram of 
included data PwMS on the Scosh MS Incidence 
Register by year of diagnosis
(2010 n =  430)
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(2012 n =   449)
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Total records screened
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Excluded for lack of 
address
(n = 36)
Records screened for 
inclusion in age-
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whilst the sex ratio varies regionally, in each region the 
lifetime risk for females is higher than for males. How-
ever, the degree of variation in incidence is such that the 
lifetime risk for males in Shetland (8.63), Orkney (7.94) 
and Tayside (6.89) is higher than for females in some other 
areas (for example, Lanarkshire (6.60), Lothian (6.98), and 
Greater Glasgow and Clyde (7.56)). Table 3 presents the 
Fig. 2  Age- and sex-stratum-
specific incidence rates for 
whole study period 2010–2017
Fig. 3  Age-adjusted incidence rates by Health Board for period 
2010–2017. (Right) cartogram of count of cases (colour) by popula-
tion-weighted datazone (size), demonstrating distribution of popula-
tion-at-risk and cases of MS with concentration in the “central belt” 
(the region containing Glasgow and Edinburgh). Population-weighted 
“datazones” are small areal units of geography comprising several 
postcodes with mean population ~ 800 persons
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calculated male, female and combined lifetime risk (CIR) 
by Health Board.
Discussion
This work provides the first report of standardized regional 
incidence rates for MS in Scotland based on the recently 
established SMSR which is the result of substantial far-
sighted public investment. The high level of completeness 
of these data (99% for age, sex and address at diagnosis) 
is a result of mandatory reporting, the CHI system which 
incorporates sex and date of birth, and the importance of 
current address for the functioning of normal service within 
the NHS.
This study builds on a strong track record of several dec-
ades of MS epidemiological surveys in Scotland and utilizes 
the SMSR for its particular advantages for aetiological inves-
tigation: chiefly, that the register is truly national, is aiming 
for complete ascertainment, and has a prospective, incidence 
design. Until the recent emergence of disease-modifying 
treatments (DMTs), prevalence, mortality, hospital admis-
sion and even disability pensioning rates were comparable 
across regions relatively unaffected by differences in medical 
services available. However, an improved therapeutic arse-
nal now potentially confounds comparisons of these rates as 
regional discrepancies in care provision or practice may now 
also affect disability, admissions and survival. A strength, 
therefore, is that the SMSR captures incidence data, which is 
inherently more biologically meaningful than other rates—
especially in the era of DMTs.
The national crude incidence rate of 8.71/105 pys con-
firms Scotland as a high-incidence nation, although not the 
highest reported internationally. The standardized incidence 
we report (8.54) is lower than recent studies from other high-
income countries. For example, in Denmark at 9.43 (95% CI 
9.17–9.69) [16] and Wales at 9.10 (95% CI 8.80–9.40) [17] 
per  105 pys. However, given the incidence register excludes 
possible MS and all cases are confirmed as definite by the 
diagnosing neurologist, it is likely that the rates we present 
reflect a lower bound on the estimate of the full burden of 
the condition in Scotland. Further, newly recognized clinical 
entities (such as neuromyelitis optica spectrum disorders), 
which in previous generations may have been included for 
calculation of MS rates, will now not be included. Caution 
may be merited in comparing these rates to those obtained 
in other settings by different methods. Our data support the 
assessment of the Scottish Public Health Observatory, that 
the SMSR is now the gold standard estimates of incidence 
in Scotland [18].
Given substantial regional variation, previous published 
estimates extrapolating prevalence from samples taken 
from single regions and/or using other methods may have 
erroneously estimated the burden of the disease in Scot-
land. Choice of index region and method of ascertainment 
are important potential sources for bias. A previous esti-
mate, for example, of 10,000 prevalent cases would only 
be plausible if our figures represented an epidemic since 
2010 and we suspect this to be a large underestimate [19]. 
Another estimate of 13,328 pwMS in 2010 derived from 
GP data supported by hospital episode data [10] appears 
more plausible. However, by roughly extrapolating preva-
lence from these incidence data, using life-expectancy and 
Fig. 4  Distribution of age at 
diagnosis by Health Board 
region. Points represent cases. 
Ordered by case number (n) 
over the study period. Vertical 
red line represents median age 
at diagnosis for that region
 Journal of Neurology
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estimates of effects of MS diagnosis on early mortality 
[20], we suspect that this may also fall short. A recent 
study, using administrative data in the USA, has sug-
gested that the prevalence of MS there may be as high as 
double that previously reported [21]. Similarly, we sus-
pect that the burden of MS in Scotland may have been 
underestimated.
Our finding of differences in incidence rates by region 
agree with those estimated by Handel et al. [11] using differ-
ent methods (hospital admissions) and our simulations dem-
onstrate these differences are unlikely to have arisen due to 
chance (Table 1 and supplementary Fig. 1). This correlation 
between studies across distinct periods is externally con-
sistent with reports of regional variability persisting across 
generations in other countries (where intergenerational cor-
relation has been reported as r ~ 0.8) [6]. The consistency 
across two methods—our study corroborating their findings 
of threefold variation (r = 0.85, p < 0.001), finding the same 
regions to be high and low incidence, whilst using a more 
robust dataset, and in a different patient cohort—leads us to 
conclude that regional variation in Scotland is real, persis-
tent and not explained by chance or bias.
In fact, a limitation of our methods is that address at the 
time of diagnosis is presumed to be an imperfect proxy for 
address at the time of onset and at the time of exposure to 
environmental risk factors [22]. Our study would thus be 
strengthened by data on pre-diagnosis location of residence. 
We would expect the imperfect correlation between loca-
tion of residence at diagnosis and exposure to have diluted 
regional variation and so, despite finding large variations, we 
may have underestimated the extent of this effect.
The regional variation, even on the relatively ancestrally 
homogenous mainland, we find to be surprisingly large. 
Regional differences in CIR, which can be interpreted 
as a hypothetical lifetime risk, range substantially, from 
19.9/1000 for females in Orkney (55.98°N) to 1.7/1000 for 
males in the Borders (55.60°N) (Table 3). And in 6 of 14 
Scottish Health Boards the lifetime risk for women exceeds 
1%. However, surprisingly, variation in incidence and sex 
ratio is of the degree that in some Health Boards of Scotland 
the lifetime risk for men exceeds the lifetime risk for women 
in other regions, despite an overall sex ratio of 2.3 (at the 
expense of women).
The variation in sex ratio between regions may be the 
result of chance. The negative correlation between sex ratio 
and latitude (greater proportion of females at low latitudes) 
in our unweighted analyses is in line with international 
trends [23]. However, the Borders and Shetland are out-
lier regions. No convincing linear relationship between sex 
ratio and latitude exists outwith these areas or on weighted 
analyses. However, the sex ratio of MS has been reported 
to have changed over decades, for example, in Canada [24] 
and Denmark [16], implicating changes in an environmental 
risk factor(s) for which males and females have differential 
sensitivity or exposures. Therefore, analysis of the regional 
sex ratio of future cases may be informative in demonstrat-
ing that these outliers arose due to chance, as we cannot yet 
exclude the possibility that they are the product of some 
local environmental factor.
Latitude predicts only a small proportion of the total vari-
ability in Scotland, but does remain significant even after 
controlling for population age–sex structure. This is perhaps 
in contrast to other Western European countries where it has 
been suggested that latitude’s association with incidence has 
diminished over time or was artefactually overestimated due 
to ascertainment issues or failure to standardize populations 
[25]. However, as northern populations in Scotland are typi-
cally more rural and have more outdoor work, it has been 
questioned—with empirical support—as to whether vitamin 
D levels robustly correlate with latitude in Scotland [26]. In 
addition, the lower incidence in Shetland, by far the most 
northerly point in Scotland, compared to Orkney and Tay-
side, raises further questions [26]. The remoteness of Shet-
land, with its distinct ancestry and—to an extent—culture, 
could explain the deviation from the general trend. How-
ever, this phenomenon, of a reversal of the latitude effect at 
extreme high latitudes, is actually consistent with interna-
tional reports. For example, the same reversal has been noted 
in Scandinavia and Russia [25]. Nevertheless, even if some 
other factor explains the proportion of variation associated 
with latitude in the rest of Scotland, it is our opinion that 
this would not be any evidence against the importance of 
hypovitaminosis D in general, given international trends and 
multiple lines of evidence [27]. Hypovitaminosis D is widely 
Table 3  Cumulative incidence rates (approximation of hypothetical 
lifetime risk)
Health Board CIR (per/1000)
All Female Male
Ayrshire and Arran 7.24 9.97 4.28
Borders 4.98 8.12 1.65
Dumfries and Galloway 7.74 10.41 4.90
Fife 7.97 10.89 4.90
Forth Valley 6.82 9.70 3.73
Grampian 7.58 9.98 5.17
Greater Glasgow and Clyde 5.45 7.56 3.22
Highland 9.36 13.05 5.60
Lanarkshire 4.80 6.60 2.91
Lothian 5.17 6.98 3.30
Orkney 13.86 19.88 7.94
Shetland 8.66 8.68 8.63
Tayside 9.61 12.22 6.89
Western Isles 7.51 10.80 4.38
National 6.55 8.90 4.10
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prevalent in Scotland and may significantly contribute to the 
burden of MS [26].
This study uses routinely collected data with attendant 
methodological limitations. For example, it is not possible 
to exclude some regional variation in case ascertainment, 
although overall ascertainment is thought to be high suggest-
ing that any such variation is probably small. Also, whilst 
the mean age at diagnosis (41.34 years) was somewhat 
higher in our study than in a clinically validated cohort from 
the UK MS register that does not include pwMS in Scotland 
(37.4 years) [28], the similar patterns of age at diagnosis 
across Health Boards is an argument against there being 
systematic differences in diagnostic efficiency by region in 
Scotland. Possible explanations for this discrepancy include: 
differences in proportions of patients by type of MS at onset 
in these two cohorts, an ageing population, truncation of the 
SMSR at young ages due to exclusion of cases with paedi-
atric onset (age < 16 years old), and/or delays in diagnosis 
due to waiting times to see a neurologist. For example, it 
may be that younger median age at diagnosis in Glasgow, 
the only region where post hoc testing identified a signifi-
cant difference (relative to two other areas), could, in part, 
reflect access to tertiary neurological care or waiting times 
to see neurologists. However, local differences in services 
and diagnostic preferences (e.g. propensity to request a lum-
bar puncture prior to diagnosis), and/or net rural-to-urban 
migration skewing the population-at-risk, will also be con-
tributory factors, in addition to chance variation.
Conclusion
This paper presents the first 8 years of the SMSR, a pro-
spective national incidence register. We confirm the high 
incidence of MS in Scotland, suggest that previous estimates 
of prevalence are likely underestimates, and corroborate pre-
vious reports of threefold variation by Health Board region 
suggesting these differences are both persistent and real. 
This has implications for service provision and supports 
further study to better understand the basis of regional vari-
ability. It raises the possibility that biologically important 
risk factors may be variably distributed in Scotland, at least 
regionally, and future work is now possible to determine if 
variation exists at a more local scale.
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